Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067060 | 0.82 | CHKA (0.34) | CYP1A2CYP2C9MAPTALDH1A1TSHR | |
| SCHEMBL918905 | 0.82 | CHKA (0.39) | LMNACYP1A2CYP2C9HTTMAPT | |
| SCHEMBL185803 | 0.81 | HPGD (0.39) | LMNACYP1A2CYP2C9MAPTRAB9A | |
| SCHEMBL22530378 | 0.80 | LMNA (0.31) | LMNAPOLBCYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL3547725 | 0.78 | AR (0.35) | MAPTRAB9AALDH1A1GAAL3MBTL1 | |
| SCHEMBL526372 | 0.78 | PLD1 (0.44) | CYP1A2HTTALDH1A1KDM4EMAPK1 | |
| SCHEMBL933508 | 0.78 | HTR3A (0.42) | CYP1A2ALDH1A1KDM4E | |
| SCHEMBL3662514 | 0.75 | KDM4E (0.48) | LMNACYP1A2HTTMAPTNPC1 | |
| SCHEMBL14931430 | 0.74 | PDE10A (0.36) | ALDH1A1TSHRPIK3CA | |
| SCHEMBL4281399 | 0.71 | KMT2A (0.45) | LMNACYP1A2CYP2C9HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 502 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634975-B1 | 17-OXIMES OF 15.BETA.-[3-PROPANAMIDO]-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES FOR USE IN INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASES | ORGANON R&D FINLAND LTD (FI) | 2024-02-28 | — | — | EP | claimed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | claimed |
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | claimed |
| EP-4251615-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-10-04 | — | — | EP | claimed |
| CN-116406362-A | Spiro [3.3] heptane derivatives for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-07-07 | — | — | CN | claimed |
| CN-110945007-B | 15 beta- [ 3-propionylamino ] -substituted estra-1, 3,5 (10) -trien-17-one compounds and 17-oximes thereof for inhibiting 17 beta-hydroxysteroid dehydrogenases | 佛恩多制药有限公司 | 2022-11-18 | — | — | CN | claimed |
| WO-2022112188-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-02 | — | — | WO | claimed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | claimed |
| US-20220127303-A1 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | FORENDO PHARMA LTD (FI) | 2022-04-28 | — | — | US | claimed |
| WO-2006061415-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-15 | — | — | WO | claimed |
| WO-2005118071-A2 | TETRAHYDROPYRIDOTHIOPHENES | ALTANA PHARMA AG (DE) | 2005-12-15 | — | — | WO | claimed |
| US-20040229917-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | claimed |
| US-20040048895-A1 | Caspase-1 inhibitors and methods for their use | SUNESIS PHARMACEUTICALS, INC. | 2004-03-11 | — | — | US | claimed |
| WO-2003103599-A2 | CASPASE-1 INHIBITORS AND METHODS FOR THEIR USE | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | claimed |
| US-6646010-B2 | Enzyme inhibitors such as N(3-benzyloxycarbonylamino-2-hydroxy -4-phenylbutyl)-N-isoamylamine, used for prophylaxis of viral diseases and infections; lymphadenopathy associated virus | G. D. SEARLE & CO. | 2003-11-11 | — | — | US | claimed |
| EP-1230235-A1 | COMPOUNDS WITH ANTIBACTERIAL AND ANTIPARASITIC PROPERTIES | New Pharma Research Sweden AB (SE) | 2002-08-14 | — | — | EP | claimed |
| WO-2001036408-A1 | COMPOUNDS WITH ANTIBACTERIAL AND ANTIPARASITIC PROPERTIES | NEW PHARMA RESEARCH SWEDEN AB (SE) | 2001-05-25 | — | — | WO | claimed |
| US-4831027-A | USEFUL IN TREATMENT OF CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1989-05-16 | — | — | US | claimed |
| EP-0263352-A1 | Imidazo-benzoxazinones, their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1988-04-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127303-A1 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | HSD17B11, NR5A1, CYP17A1 | LMNA 2049/4885POLB 4418/4885CYP1A2 65/4885 |
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR1I3, NR1H4 | LMNA 1803/4885POLB 1692/4885CYP1A2 41/4885 |
| US-20040048895-A1 | Caspase-1 inhibitors and methods for their use | CASP1, CASP2, CASP9 | LMNA 177/4885POLB 4140/4885CYP1A2 287/4885 |
| US-20040229917-A1 | Imidazole derivatives | GRIK4, GRIA4, GRIK5 | LMNA 4524/4885POLB 4532/4885CYP1A2 3311/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | LMNA 1854/4885POLB 2998/4885CYP1A2 1905/4885 |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | LMNA 3893/4885POLB 3823/4885CYP1A2 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.